Elizabeth Bell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Interests
Elizabeth Bell has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Z. P. Friedman
Department of Medicine Section of Infectious Diseases and Global Health University of Chicago Chicago Illinois USA
2 shared publications Jennifer Pisano
Section of Infectious Diseases & Global Health, University of Chicago , Chicago, Illinois , USA
2 shared publications- Alison K. Lew
Department of Pharmacy, University of Chicago Medicine, Chicago, IL, USA
1 shared publication - Benjamin Chastek
Optum, Eden Prairie, MN 55344, USA
1 shared publication - Christopher Lehmann
Duchossois Family Institute, University of Chicago, Chicago, IL 60637, USA
1 shared publication Cynthia T. Nguyen
Department of Pharmacy, University of Chicago Medicine, Chicago, IL, USA
1 shared publication
Latest Publications
- Open Access
- 4 October 2024
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 45 (11) , 1286-1292
Fidaxomicin versus oral vancomycin for Clostridioides difficile infection among patients at high risk for recurrence based on real-world experience
Introduction: Clostridioides difficile infection (CDI) is a common nosocomial infection and is associated with a high healthcare burden due to high rates of recurrence. In 2021 the IDSA/SHEA guideline update recommended fidaxomicin (FDX) as first-line therapy. Our medical center updated our institutional guidelines to follow these recommendations, prioritizing FDX use among patients at high risk for recurrent CDI (rCDI).Methods: This pre- post- quasi-experimental study included patients with a presumptive diagnosis of CDI at risk for recurrence (age >/= 65 years, immunocompromised, severe CDI) that received vancomycin (VAN) or FDX between October 2019 to October 2022. Patients who received bezlotoxumab, had fulminant CDI, or received P = 0.86), subsequent CDI within 12 months of therapy completion of therapy (19.4% vs 26%, P = 0.12) and 30-day CDI-related readmissions (3% vs 4.5%, P = 0.6) were similar between patients who received VAN versus FDX.Conclusion: Outcomes were similar between patients treated with FDX and VAN for the treatment of CDI among those at high risk for rCDI, using our outlined criteria. Although we observed a trend toward lower rates of rCDI among immunocompromised patients, this finding was not significant. Further investigation is needed to determine which patients with CDI may benefit from FDX.
- 4 October 2024
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 45 (11) , 1286-1292
Open AccessFidaxomicin versus oral vancomycin for Clostridioides difficile infection among patients at high risk for recurrence based on real-world experience
Introduction: Clostridioides difficile infection (CDI) is a common nosocomial infection and is associated with a high healthcare burden due to high rates of recurrence. In 2021 the IDSA/SHEA guideline update recommended fidaxomicin (FDX) as first-line therapy. Our medical center updated our institutional guidelines to follow these recommendations, prioritizing FDX use among patients at high risk for recurrent CDI (rCDI).Methods: This pre- post- quasi-experimental study included patients with a presumptive diagnosis of CDI at risk for recurrence (age >/= 65 years, immunocompromised, severe CDI) that received vancomycin (VAN) or FDX between October 2019 to October 2022. Patients who received bezlotoxumab, had fulminant CDI, or received P = 0.86), subsequent CDI within 12 months of therapy completion of therapy (19.4% vs 26%, P = 0.12) and 30-day CDI-related readmissions (3% vs 4.5%, P = 0.6) were similar between patients who received VAN versus FDX.Conclusion: Outcomes were similar between patients treated with FDX and VAN for the treatment of CDI among those at high risk for rCDI, using our outlined criteria. Although we observed a trend toward lower rates of rCDI among immunocompromised patients, this finding was not significant. Further investigation is needed to determine which patients with CDI may benefit from FDX.
- Open Access
- 20 May 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (6) , ofae292
Reply to Heldman et al
Elizabeth Bell, M.D, Jennifer Pisano, Daniel Friedman; Reply to Heldman et al, Open Forum Infectious Diseases, , ofae292, https://doi.org/10.1093/ofid/ofae
- 20 May 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (6) , ofae292
Open AccessReply to Heldman et al
Elizabeth Bell, M.D, Jennifer Pisano, Daniel Friedman; Reply to Heldman et al, Open Forum Infectious Diseases, , ofae292, https://doi.org/10.1093/ofid/ofae
- Open Access
- 16 March 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (6) , ofae158
An Unexpectedly High Incidence of Invasive Fungal Diseases in Solid Organ Transplant Recipients Taking Belatacept for Organ Rejection Prophylaxis: A Single-Center Retrospective Cohort Study
Among solid organ transplant recipients taking belatacept, 15% developed invasive fungal diseases. The most common invasive fungal diseases were aspergillosis (56%) and candidiasis (22%). The infected cohort was more likely to receive basiliximab, undergo lung transplantation, or identify as White. Higher rates of aspergillosis were seen in this lung cohort than previously reported.
- 16 March 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (6) , ofae158
Open AccessAn Unexpectedly High Incidence of Invasive Fungal Diseases in Solid Organ Transplant Recipients Taking Belatacept for Organ Rejection Prophylaxis: A Single-Center Retrospective Cohort Study
Among solid organ transplant recipients taking belatacept, 15% developed invasive fungal diseases. The most common invasive fungal diseases were aspergillosis (56%) and candidiasis (22%). The infected cohort was more likely to receive basiliximab, undergo lung transplantation, or identify as White. Higher rates of aspergillosis were seen in this lung cohort than previously reported.
- Open Access
- 26 July 2022
- Published by Springer Nature in BMC Gastroenterology
- Vol. 22 (1) , 1
Correction to: Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis
- 26 July 2022
- Published by Springer Nature in BMC Gastroenterology
- Vol. 22 (1) , 1
Open AccessCorrection to: Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis
- 1 January 2021
- Published by Elsevier in The American Journal of Medicine
- Vol. 134 (1) , 57-59
Progressive Dyspnea and Pleural Effusion—When the Answer Lies Buried in the History
- 1 January 2021
- Published by Elsevier in The American Journal of Medicine
- Vol. 134 (1) , 57-59
Progressive Dyspnea and Pleural Effusion—When the Answer Lies Buried in the History